Opus Genetics & Global RDH12 Alliance partner to advance RDH12 gene therapy for inherited childhood blindness
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, announced a strategic partnership with the Global RDH12 Alliance (the Alliance) to advance Opus’ gene therapy programme for patients with vision loss due to retinol dehydrogenase 12 (RDH12) …